Autotaxin

PAT-347 is a type III Autotaxin inhibitor that has inhibits autotaxin with IC50 in the nanomolar range.

Biochemical Assay with FS-3 Substrate[2]
Starting from 20 μM highest concentration, 10 μL of a dilution series of compound, 1/5 dilution, was added to the wells. Glycosylated human ATX protein (see Supporting Information) was used at a final concentration of 0.4 or 0.64 μg/mL. The enzyme was diluted in 50 mM Tris-HCl (2-amino-2-(hydroxymethyl)-1,3-propanediol hydrochloride) pH 8.0, 250 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, and 0.1% fatty acid free BSA in a total volume of 20 μL. The enzyme mixture was added to compounds, and the resulting mixture was incubated for 30 min at room temperature under shaking. The reaction was started by the addition of 20 μL of 0.75 μM FS-3 diluted in the same buffer as described above. Fluorescence was read on an Envision apparatus after 30 min incubation at room temperature (excitation 485 nm, emission 520 nM).[2]

---

Biochemical Assay with LPC 16:0 Substrate[2]
Starting from 20 μM highest concentration, 5 μL of a dilution series of compound (1/5 dilution) was added to the wells. Glycosylated human ATX protein (see Supporting Information) was used at a final concentration of 1 or 3 μg/mL. The enzyme was diluted in 50 mM Tris-HCl pH 8.5, 500 mM NaCl, 5 mM KCl, 10 mM CaCl2, and 0.1% fatty acid free BSA in a total volume of 10 μL. The reaction was started by the addition of 10 μL of 150 μM LPC 16:0 diluted in the same buffer as described above, and the mixture was incubated at 37 °C for 30 min. The reaction was terminated and choline quantified by the addition of a 25 μL mixture containing 0.6 U/mL of choline oxidase, 0.6 U/mL of horseradish peroxidase (HRP), 1.8 mM TOOS (N-ethyl-N-(2-hydroxy-3-sulfopropyl)-3-methylaniline, sodium salt dihydrate), 1.2 mM 4-aminoantipyrine, and 20 mM EGTA (ethylene glycol-bis(2-aminoethyl ether)-N,N,N′,N′-tetraacetic acid, stop-developer solution) diluted in the buffer described above. Luminescence was read on an Envision apparatus after 30 min of incubation at room temperature (excitation 555 nm, excitation light = 70%).[2]

---

Rat Plasma Assay[2]
Rat plasma was thawed on ice and added into a plate containing a dose range of compound to be tested. After 2 h of incubation at 37 °C, plasma proteins from a 10 μL aliquot were precipitated with an excess of methanol containing LPA 17:0 as internal standard. After centrifugation, the corresponding supernatant was diluted and injected on a C18 column. Analytes were eluted out of the column under isocratic conditions. No calibration curve was prepared for LPA 18:2, and all quantifications were performed based on peak area ratios (LPA 18:2/LPA 17:0). For each concentration of compound, LPA data were expressed as percentage of reduction (% reduction) using the formula: 100 – [((LPA ratio)/(LPA ratio in control sample)) × 100]

[1]. Chen Y, et al. Design, synthesis and anti-fibrosis evaluation of imidazo [1, 2–a] pyridine derivatives as potent ATX inhibitors[J]. Bioorganic & Medicinal Chemistry, 2021, 46: 116362.
[2]. Joncour A, et al. Discovery, structure–activity relationship, and binding mode of an imidazo [1, 2-a] pyridine series of autotaxin inhibitors[J]. Journal of Medicinal Chemistry, 2017, 60(17): 7371-7392.

Autotaxin (ATX) is a secreted enzyme playing a major role in the production of lysophosphatidic acid (LPA) in blood through hydrolysis of lysophosphatidyl choline (LPC). The ATX–LPA signaling axis arouses a high interest in the drug discovery industry as it has been implicated in several diseases including cancer, fibrotic diseases, and inflammation, among others. An imidazo[1,2-a]pyridine series of ATX inhibitors was identified out of a high-throughput screening (HTS). A cocrystal structure with one of these compounds and ATX revealed a novel binding mode with occupancy of the hydrophobic pocket and channel of ATX but no interaction with zinc ions of the catalytic site. Exploration of the structure–activity relationship led to compounds displaying high activity in biochemical and plasma assays, exemplified by compound 40. Compound 40 was also able to decrease the plasma LPA levels upon oral administration to rats.[2]

C28H21CLF2N2O3S

538.992751836777

538.09

C, 62.40; H, 3.93; Cl, 6.58; F, 7.05; N, 5.20; O, 8.90; S, 5.95

1689554-51-5

2650082-35-0 (sodium); 1689554-51-5 (free acid)

91936957

Typically exists as solid at room temperature

6.3

1

6

5

37

909

0

YFALJJNRFPFPRE-UHFFFAOYSA-N

InChI=1S/C28H21ClF2N2O3S/c1-15-26(37-21-8-4-5-16(23(21)30)27(35)36)17-9-10-19(29)24(31)25(17)32(15)13-22(34)33-14-28(11-12-28)18-6-2-3-7-20(18)33/h2-10H,11-14H2,1H3,(H,35,36)

3-[6-chloro-7-fluoro-2-methyl-1-(2-oxo-2-spiro[2H-indole-3,1'-cyclopropane]-1-ylethyl)indol-3-yl]sulfanyl-2-fluorobenzoic acid

PAT-347; 1689554-51-5; 3-({6-Chloro-7-Fluoro-2-Methyl-1-[2-Oxo-2-(Spiro[cyclopropane-1,3'-Indol]-1'(2'h)-Yl)ethyl]-1h-Indol-3-Yl}sulfanyl)-2-Fluorobenzoic Acid; CHEMBL4117054; SCHEMBL16600569; YFALJJNRFPFPRE-UHFFFAOYSA-N;

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

---

Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).

View More

Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline)

---

Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).

View More

Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

---

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

---

 (Please use freshly prepared in vivo formulations for optimal results.)